Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ROS1-positive Non-Small Cell Lung Cancer (NSCLC)”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Not applicableUnknownNCT05110950
What this trial is testing

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Who this might be right for
Mediastinal LymphadenopathyHilar LymphadenopathyLymphoma+7 more
Università Politecnica delle Marche 306
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Testing effectiveness (Phase 2)UnknownNCT03972189
What this trial is testing

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 111
Not applicableNo Longer AvailableNCT06841874
What this trial is testing

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Who this might be right for
Lung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms+8 more
Nuvation Bio Inc.
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT05297890
What this trial is testing

Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals 70
Not applicableAvailableNCT06797362
What this trial is testing

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Who this might be right for
Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Nuvalent Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05765877
What this trial is testing

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer(NSCLC)
Pingping Song 26
Testing effectiveness (Phase 2)Looking for participantsNCT04996121
What this trial is testing

XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 360
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07083687
What this trial is testing

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer (NSCLC)
Hunan Cancer Hospital 21
Testing effectiveness (Phase 2)UnknownNCT03439215
What this trial is testing

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06140836
What this trial is testing

Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb 190
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Large-scale testing (Phase 3)Not Yet RecruitingNCT07154368
What this trial is testing

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Who this might be right for
Non Small Cell Lung Cancer
Guangzhou JOYO Pharma Co., Ltd 207
Large-scale testing (Phase 3)Looking for participantsNCT06564324
What this trial is testing

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 194
Load More Results